Foundation Medicine Inc.'s pan-cancer detection test has received a nod from the FDA making it one of the most comprehensive companion diagnostics to receive approval from the agency. Concurrent with FDA approval, the Centers for Medicare & Medicaid Services issued a preliminary National Coverage Determination (NCD) for the Foundationone Cdx.